Statins do not reduce the parasite burden during experimentalTrypanosoma cruziinfection
Abstract
Cardiomyopathy is the most common pathology associated withTrypanosoma cruziinfection. Reports that statins have both cardioprotective and trypanocidal activity have generated interest in their potential as a therapeutic treatment. Using a highly-sensitive bioluminescent mouse model, we show that 5 days treatment with statins has no significant impact on parasite load. The free systemic concentrations fail to reach the level required for potency. Hence, clinical trials to investigate trypanocidal activity of statins lack experimental justification.
Related articles
Related articles are currently not available for this article.